Lipid Disorder Treatment Market - Forecasts from 2019 to 2024
Global lipid disorder treatment market is projected to grow at a CAGR of 4.21% to reach US$5.509 billion by 2024, from US$4.302 billion in 2018. Lipids, or lipoproteins, are the fats found circulating in the bloodstream. Lipid disorders refer to a broad spectrum of metabolic conditions that affect blood lipid levels. They are generally characterized by elevated levels of cholesterol, triglycerides, and/or lipoproteins in the blood in association with an increased risk of (or current) cardiovascular disease. There are a number of easy ways to lower your LDLs, including avoiding foods high in saturated fat, dietary cholesterol, and excess calories; exercising; maintaining a healthy weight; and stopping smoking. Statins are the most commonly prescribed treatments for lipid treatments.
Increasing adoption of unhealthy lifestyles by consumers has increased various lifestyle diseases around the globe. Increasing prevalence of high cholesterol levels along with the increasing developments in the treatment for lipid metabolism disorders will further augment the market. According to World Health Organization a third of ischemic heart disease is attributable to high cholesterol levels. Moreover smoking and drinking have also contributed to the rising prevalence of lipid disorder, which further fuel the growth of the market.
The Lipid Disorder Treatment Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by drug type, distribution channel, and geography.
Based on techniques, the market has been segmented as Non-invasive and Invasive. On the basis of indication, the market is segmented as genetic diseases and infectious diseases. Based on End-Users, the market has been segmented as Hospitals and Clinics and Diagnostic Labs.
Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the lipid disorder treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in lipid disorder treatment market.
Segmentation:
Increasing adoption of unhealthy lifestyles by consumers has increased various lifestyle diseases around the globe. Increasing prevalence of high cholesterol levels along with the increasing developments in the treatment for lipid metabolism disorders will further augment the market. According to World Health Organization a third of ischemic heart disease is attributable to high cholesterol levels. Moreover smoking and drinking have also contributed to the rising prevalence of lipid disorder, which further fuel the growth of the market.
The Lipid Disorder Treatment Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by drug type, distribution channel, and geography.
Based on techniques, the market has been segmented as Non-invasive and Invasive. On the basis of indication, the market is segmented as genetic diseases and infectious diseases. Based on End-Users, the market has been segmented as Hospitals and Clinics and Diagnostic Labs.
Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the lipid disorder treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in lipid disorder treatment market.
Segmentation:
- By Drug Type
- Lovastatin
- Atorvastatin
- Rosuvastatin
- Others
- Distribution Channel
- Online
- Offline
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- Italy
- Spain
- Others
- Middle East and Africa (MEA)
- Israel
- Saudi Arabia
- Others
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. LIPID DISORDER TREATMENT MARKET BY DRUG TYPE
5.1. Lovastatin
5.2. Atorvastatin
5.3. Rosuvastatin
5.4. Others
6. LIPID DISORDER TREATMENT MARKET BY DISTRIBUTION CHANNEL
6.1. Online
6.2. Offline
7. LIPID DISORDER TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. UK
7.3.2. Germany
7.3.3. Italy
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Israel
7.4.2. Saudi Arabia
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. Australia
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. COMPANY PROFILE
9.1. Pfizer
9.2. Mylan
9.3. Teva Pharmaceuticals
9.4. Sun Pharmaceuticals Industries Ltd.
9.5. Merck & Co.
List is not exhaustive
List of Figures
List of Tables
Disclaimer
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. LIPID DISORDER TREATMENT MARKET BY DRUG TYPE
5.1. Lovastatin
5.2. Atorvastatin
5.3. Rosuvastatin
5.4. Others
6. LIPID DISORDER TREATMENT MARKET BY DISTRIBUTION CHANNEL
6.1. Online
6.2. Offline
7. LIPID DISORDER TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. UK
7.3.2. Germany
7.3.3. Italy
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Israel
7.4.2. Saudi Arabia
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. Australia
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. COMPANY PROFILE
9.1. Pfizer
9.2. Mylan
9.3. Teva Pharmaceuticals
9.4. Sun Pharmaceuticals Industries Ltd.
9.5. Merck & Co.
List is not exhaustive
List of Figures
List of Tables
Disclaimer
